Localized Scleroderma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: LCL006 MIFTS: 61	Localized Scleroderma Categories: Bone diseases, Immune diseases, Nephrological diseases, Rare diseases, Respiratory diseases, Skin diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Localized Scleroderma

MalaCards integrated aliases for Localized Scleroderma:

Name: Localized Scleroderma ¹¹ ¹⁹ ⁵⁸ ¹⁴ ⁷¹ ⁷⁵

Morphea ¹¹ ¹⁹ ⁵³ ⁷¹ ⁷⁵

Localized Fibrosing Scleroderma ¹⁹ ⁵⁸

Localised Scleroderma ¹¹ ¹⁶

Scleroderma, Circumscribed or Localised ¹¹

Scleroderma, Circumscribed or Localized ¹¹

Circumscribed Scleroderma ¹¹

Scleroderma, Localized ¹⁹

Localised Morphoea ¹¹

Localised Morphea ¹¹

Localized Morphea ¹¹

Characteristics:

Prevelance:

1-9/100000 (Europe) ⁵⁸

Age Of Onset:

All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Skin diseases Immune diseases Nephrological diseases Respiratory diseases Bone diseases

See all MalaCards categories (disease lists)

ICD10: ³¹ ³²

Diseases of the skin and subcutaneous tissue

Other disorders of the skin and subcutaneous tissue

Other localized connective tissue disorders

Localized scleroderma [morphea]

Orphanet: ⁵⁸

Rare skin diseases

Sources

Summaries for Localized Scleroderma

GARD: ¹⁹ Localized scleroderma is characterized by thickening of the skin from excessive collagen deposits. Collagen is a protein normally present in our skin that provides structural support. However, when too much collagen is made, the skin becomes stiff and hard. Localized types of scleroderma are those limited to the skin and related tissues and, in some cases, the muscle below. Internal organs are not affected by Localized scleroderma, and Localized scleroderma can never progress to the systemic form of the disease. Often, localized conditions improve or go away on their own over time, but the skin changes and damage that occur when the disease is active can be permanent. For some people, Localized scleroderma is serious and disabling. There are two generally recognized types of Localized scleroderma: morphea and linear.

MalaCards based summary: Localized Scleroderma, also known as morphea, is related to facial hemiatrophy and scleroderma, familial progressive, and has symptoms including pruritus and exanthema. An important gene associated with Localized Scleroderma is MMP1 (Matrix Metallopeptidase 1), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lidocaine and Anti-Arrhythmia Agents have been mentioned in the context of this disorder. Affiliated tissues include skin, lung and skeletal muscle, and related phenotypes are thickened skin and arthralgia

Orphanet: ⁵⁸ Localized scleroderma is the skin localized form of scleroderma (see this term) characterized by fibrosis of the skin causing cutaneous plaques or strips.

Wikipedia: ⁷⁵ Morphea is a form of scleroderma that involves isolated patches of hardened skin on the face, hands, and... more...

Sources

Related Diseases for Localized Scleroderma

Diseases in the Systemic Scleroderma family:

Scleroderma, Familial Progressive

Localized Scleroderma

Diseases related to Localized Scleroderma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 910)

#	Related Disease	Score	Top Affiliating Genes
1	facial hemiatrophy	32.0	SNRNP70 EXOSC10
2	scleroderma, familial progressive	31.4	TOP1 FBN1 COL1A2 CCN2
3	fasciitis	30.6	TNF MMP1 IL6 CD34
4	skin atrophy	30.5	TNF IL4 H2AC18
5	autoimmune disease	30.4	TNF IL6 IL4 IL2RA IL13
6	crest syndrome	30.4	TOP1 SNRNP70 H2AC18 EXOSC10
7	diffuse scleroderma	30.4	TSSK1B TOP1 SNRNP70 EXOSC10 CCN2
8	uveitis	30.3	TNF IL6 IL4 IL2RA
9	basal cell carcinoma	30.3	TNF MMP1 IL6 H2AC18 CD34
10	purpura	30.2	TNF IL6 IL4
11	granuloma annulare	30.2	TNF CD8A CD4
12	thyroiditis	30.2	TNF IL6 IL4
13	scleredema adultorum	30.1	MMP1 FBN1 DCN CD8A
14	dermatitis	30.0	TNF IL6 IL4 IL13
15	esophagitis	30.0	TNF IL6 IL4 IL13
16	covid-19	30.0	TNF IL6 IL4 IL2RA
17	lichen planus	30.0	TNF IL6 IL4
18	folliculitis	30.0	TNF IL4 CD4
19	juvenile rheumatoid arthritis	29.9	TNF IL6 IL2RA CD4
20	schistosomiasis	29.9	TNF IL4 IL13
21	collagen disease	29.9	SNRNP70 IL6 H2AC18 FBN1 EXOSC10 DCN
22	panniculitis	29.9	IL2RA CD8A CD4
23	adult syndrome	29.9	TNF IL6 H2AC18
24	vitiligo-associated multiple autoimmune disease susceptibility 1	29.9	TNF CD8A CD4
25	rubella	29.9	TNF IL6 IL4 IL2RA
26	mixed connective tissue disease	29.9	TNF SNRNP70 IL6
27	osteomyelitis	29.9	TNF MMP1 IL6 IL4 CTSK
28	granulomatous dermatitis	29.9	TNF CD8A CD4
29	marfan syndrome	29.9	MMP1 LOX FBN1 DCN COL1A2
30	systemic scleroderma	29.9	TSSK1B TOP1 TNF SNRNP70 IL6 IL4
31	hashimoto thyroiditis	29.9	IL4 IL2RA H2AC18 CD8A CD4
32	septic arthritis	29.8	TNF IL6 CD4
33	henoch-schoenlein purpura	29.8	TNF IL6 CD4
34	dyskinesia of esophagus	29.8	TOP1 SNRNP70 IL13 EXOSC10
35	central nervous system vasculitis	29.8	TNF IL6 CD8A CD4
36	oral submucous fibrosis	29.8	TNF LOX COL1A2
37	chronic ulcer of skin	29.8	TNF MMP1 IL6
38	xerophthalmia	29.8	TNF CD8A CD4
39	childhood type dermatomyositis	29.8	TNF SNRNP70 EXOSC10 CD4
40	inflammatory bowel disease 1	29.8	TNF IL6 H2AC18
41	toxoplasmosis	29.7	TNF IL6 IL4
42	skin carcinoma	29.7	TNF H2AC18 CD8A CD4
43	aortic aneurysm	29.7	TNF MMP1 LOX IL6 FBN1
44	osteoarthritis	29.7	TNF MMP1 IL6 DCN CTSK
45	telangiectasis	29.7	TOP1 TNF SNRNP70 H2AC18 FBN1 EXOSC10
46	spondyloarthropathy 1	29.7	TNF IL6 CD8A CD4
47	bronchiolitis obliterans	29.7	TNF IL6 IL13
48	proteasome-associated autoinflammatory syndrome 1	29.7	TNF IL6 IL4 IL13
49	lung disease	29.7	TNF IL6 IL13 H2AC18 CCN2
50	alopecia areata	29.7	TNF IL6 IL4 IL2RA IL13

Comorbidity relations with Localized Scleroderma via Phenotypic Disease Network (PDN):

Systemic Scleroderma

Vulva Cancer

Graphical network of the top 20 diseases related to Localized Scleroderma:

Sources

Symptoms & Phenotypes for Localized Scleroderma

Human phenotypes related to Localized Scleroderma:

⁵⁸ ³⁰ (show top 50) (show all 57)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	thickened skin ⁵⁸ ³⁰	Hallmark (90%)	Very frequent (99-80%)	HP:0001072
2	arthralgia ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002829
3	stiff skin ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0030053
4	cutaneous sclerotic plaque ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0031359
5	dental malocclusion ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000689
6	arthritis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001369
7	flexion contracture ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001371
8	gastroesophageal reflux ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002020
9	myopathy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0003198
10	abnormality of vision ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000504
11	uveitis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000554
12	hypopigmented skin patches ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001053
13	migraine ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002076
14	erythema ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010783
15	infra-orbital crease ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100876
16	upper limb asymmetry ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100560
17	fasciitis ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100537
18	abnormality of upper lip ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000177
19	patchy alopecia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002232
20	hyperpigmentation of the skin ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0000953
21	erythematous plaque ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0025474
22	hemifacial atrophy ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0011331
23	sclerosis of finger phalanx ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0100899
24	progressive loss of facial adipose tissue ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0009019
25	short dental root ³⁰	Occasional (7.5%)		HP:0006336
26	abnormal cheek morphology ³⁰	Occasional (7.5%)		HP:0004426
27	abnormal facial skeleton morphology ³⁰	Occasional (7.5%)		HP:0011821
28	skeletal muscle atrophy ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0003202
29	hashimoto thyroiditis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000872
30	vitiligo ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001045
31	arrhythmia ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0011675
32	deeply set eye ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000490
33	proptosis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000520
34	stroke ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0001297
35	abnormality of the kidney ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000077
36	vasculitis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002633
37	abnormality of the nose ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0000366
38	abnormal blistering of the skin ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0008066
39	skin erosion ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0200041
40	raynaud phenomenon ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0030880
41	esophagitis ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0100633
42	focal impaired awareness seizure ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002384
43	abnormality on pulmonary function testing ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0030878
44	seizure ⁵⁸		Very rare (<4-1%)
45	abnormality of the dentition ⁵⁸		Occasional (29-5%)
46	abnormality of the cardiovascular system ⁵⁸		Very rare (<4-1%)
47	autoimmunity ⁵⁸		Occasional (29-5%)
48	facial asymmetry ⁵⁸		Occasional (29-5%)
49	headache ⁵⁸		Occasional (29-5%)
50	abnormality of the nervous system ⁵⁸		Very rare (<4-1%)

UMLS symptoms related to Localized Scleroderma:

pruritus; exanthema

GenomeRNAi Phenotypes related to Localized Scleroderma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.13	CCN2 CD34 CD4 CD8A COL1A2 CTSK
2	no effect	GR00402-S-2	10.13	CCN2 CD34 CD4 COL1A2 DCN H2AC18

MGI Mouse Phenotypes related to Localized Scleroderma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.3	CCN2 CD34 CD4 COL1A2 CTSK DCN
2	cellular	MP:0005384	10.18	CCN2 CD34 CD4 CD8A COL1A2 CTSK
3	endocrine/exocrine gland	MP:0005379	10.17	CCN2 CD4 CD8A CTSK DCN FBN1
4	immune system	MP:0005387	10.17	CD34 CD4 CD8A COL1A2 CTSK DCN
5	digestive/alimentary	MP:0005381	10.06	CCN2 CD4 CTSK DCN IL13 IL2RA
6	respiratory system	MP:0005388	9.96	CCN2 CTSK DCN FBN1 IL13 IL2RA
7	skeleton	MP:0005390	9.9	CCN2 COL1A2 CTSK DCN FBN1 IL13
8	hematopoietic system	MP:0005397	9.77	CD34 CD4 CD8A COL1A2 CTSK DCN
9	integument	MP:0010771	9.4	CCN2 CD34 CD4 CD8A COL1A2 DCN

Sources

Drugs & Therapeutics for Localized Scleroderma

Drugs for Localized Scleroderma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 146)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Anti-Arrhythmia Agents

Phase 4

Sodium Channel Blockers

Phase 4

Anesthetics, Local

Phase 4

Diuretics, Potassium Sparing

Phase 4

Macitentan

Approved

Phase 2, Phase 3

441798-33-0

16004692

Sildenafil

Approved, Investigational

Phase 3

139755-83-2, 171599-83-0

5212 135398744

Sodium citrate

Approved, Investigational

Phase 3

68-04-2

23431961

Tadalafil

Approved, Investigational

Phase 3

171596-29-5

110635

Acetylcholine

Approved, Investigational

Phase 3

51-84-3

187

Cyclophosphamide

Approved, Investigational

Phase 3

50-18-0, 6055-19-2

2907

Prednisolone phosphate

Approved, Vet_approved

Phase 3

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 3

52-21-1

Prednisolone

Approved, Vet_approved

Phase 3

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 3

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 3

83-43-2

4159 6741

Lenograstim

Approved, Investigational

Phase 3

135968-09-1

Mycophenolic acid

Approved, Investigational

Phase 3

24280-93-1

446541

Coenzyme M

Approved, Investigational

Phase 3

3375-50-6

598 23662354

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 3

77-92-9

311

Prednisolone hemisuccinate

Experimental

Phase 3

2920-86-7

4897

Endothelin A Receptor Antagonists

Phase 2, Phase 3

Pharmaceutical Solutions

Phase 3

Anesthetics

Phase 2, Phase 3

Alkylating Agents

Phase 3

Antineoplastic Agents, Alkylating

Phase 3

Anticoagulants

Phase 3

Phosphodiesterase Inhibitors

Phase 3

Phosphodiesterase 5 Inhibitors

Phase 3

Vasodilator Agents

Phase 3

Citrate

Phase 3

Calcium, Dietary

Phase 3

Neurotransmitter Agents

Phase 3

Insulin, Globin Zinc

Phase 3

Insulin

Phase 3

abobotulinumtoxinA

Phase 3

Botulinum Toxins, Type A

Phase 3

Botulinum Toxins

Phase 3

Cholinergic Agents

Phase 3

Chelating Agents

Phase 3

Immunosuppressive Agents

Phase 3

Methylprednisolone Acetate

Phase 3

584547

Antilymphocyte Serum

Phase 3

Thymoglobulin

Phase 3

Calcium

Nutraceutical

Phase 3

7440-70-2

271

Rituximab

Approved

Phase 2

174722-31-7

Abatacept

Approved

Phase 1, Phase 2

332348-12-6

Epoprostenol

Approved

Phase 2

61849-14-7, 35121-78-9

5282411

Treprostinil

Approved, Investigational

Phase 2

81846-19-7

6918140

Dasatinib

Approved, Investigational

Phase 1, Phase 2

302962-49-8

3062316

Interventional clinical trials:

(show top 50) (show all 117)

#	Name	Status	NCT ID	Phase	Drugs
1	Safety and Efficacy of Vaccination Against Influenza in Patients With Scleroderma	Unknown status	NCT01002508	Phase 4
2	The Use of Local Anesthetic in Intralesional Corticosteroid Injections; A Randomized, Double Blind Controlled Trial	Completed	NCT03630198	Phase 4	Corticosteroid with lidocaine;Corticosteroid with normal saline
3	A Phase IV, Single-arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of PLACENTEX ® Polydeoxyribonucleotide i.m. in Patients With Fibrotic and Atrophic Cutaneous Lesions in Scleroderma Diseases	Terminated	NCT03388255	Phase 4	Polydeoxyribonucleotides
4	CompRehensive Phenotypic Characterization of Patients With Scleroderma-Associated Interstitial Lung DiseasE and Pulmonary Hypertension (PH): The CRuSADE PH Study	Unknown status	NCT03726398	Phase 2, Phase 3	Opsumit 10 Mg Tablet
5	Evaluation of the Efficacy and Safety of the Imiquimod 5% Topical Cream in Plaque Morphea: A Prospective, Multiple Baseline, Open Label Pilot Study	Completed	NCT00147771	Phase 3	Imiquimod 5% cream
6	Effectiveness and Safety of Lidocaine for Scleroderma. Randomized Double-Blind Clinical Trial	Completed	NCT00740285	Phase 2, Phase 3	Lidocaine 2% without vessel constrictor
7	High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma)	Completed	NCT00501995	Phase 3	IV Cyclophosphamide
8	Cyclophosphamide Versus Placebo in Scleroderma Lung Study	Completed	NCT00004563	Phase 3	Cyclophosphamide;Placebo
9	A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma: A Double Blind, Parallel Group, Multicentric Study	Completed	NCT01117298	Phase 3	Tadalafil;Placebo
10	A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Assessing the Therapeutic Efficacy of Botulinum Toxin In Treating Scleroderma-Associated Raynaud's Syndrome	Completed	NCT02165111	Phase 3	Onabotulinumtoxin A;sterile saline solution
11	Effect of Sildenafil on the Microcirculatory Blood Flow and on the Endothelial Progenitor Cells in Patients With Systemic Sclerosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial	Completed	NCT01347008	Phase 3	Sildenafil citrate;Placebo (Sugar pill)
12	Evaluation of the Efficacy of Sildenafil on Time to Healing in Patients With Scleroderma and Ischaemic Digital Ulcers: a Prospective, Longitudinal, Randomized, Comparative, Double-blind, 2-parallel-arm, Placebo-controlled Study	Completed	NCT01295736	Phase 3	Sildenafil;placebo
13	Upfront Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Medication in Early Diffuse Cutaneous Systemic Sclerosis: an International Multicentre, Open-label, Randomized Con-trolled Trial	Recruiting	NCT04464434	Phase 3
14	Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells - A Randomized, Double-Blind, Placebo-Controlled Study - The STAR-II Trial	Not yet recruiting	NCT05148598	Phase 3
15	Evaluation of the Efficacy and Safety of Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study	Withdrawn	NCT00230373	Phase 3	imiquimod 5% cream (Aldara)
16	Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea	Completed	NCT03351114	Phase 2	Crisaborole
17	A Protocol Based Treatment for Debilitating Fibrosing Skin Disorders With (Anti-CD 20), Rituximab, Evaluating Safety and Efficacy	Completed	NCT00936546	Phase 2	Rituximab
18	Phase II Randomized Double Blind Clinical Trial of'Imatinib Mesylate STI571 (Glivec®) Versus Placebo in Patients With Severe Cutaneous Scleroderma or Systemic Sclerosis With Severe Cutaneous Involvement.	Completed	NCT00479934	Phase 2	imatinib mesylate
19	The Effectiveness of UVB Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study	Completed	NCT00129428	Phase 1, Phase 2
20	A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma	Completed	NCT02047708	Phase 2	Zibotentan
21	A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis	Completed	NCT00442611	Phase 1, Phase 2	Abatacept;Placebo
22	DISTOL-1: Digital Ischemic Lesions in Scleroderma Treated With Oral Treprostinil Diethanolamine: A Randomized, Double-blind, Placebo-controlled, Multicenter Study	Completed	NCT00775463	Phase 2	treprostinil diethanolamine;placebo
23	An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis	Completed	NCT00764309	Phase 1, Phase 2	dasatinib
24	Multicenter Phase II Trial of Oral Type I Bovine Collagen in Scleroderma	Completed	NCT00005675	Phase 2	Oral bovine type I collagen;Placebo
25	Psychosocial Interventions for Scleroderma	Completed	NCT00007267	Phase 2
26	Mycophenolate vs. Oral Cyclophosphamide in Scleroderma Interstitial Lung Disease (Scleroderma Lung Study II)	Completed	NCT00883129	Phase 2	Mycophenolate mofetil;Cyclophosphamide;Placebo
27	Trial of High Dose Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG) With Hematopoietic Stem Cell Support in Patients With Systemic Scleroderma: A Randomized Trial	Completed	NCT00278525	Phase 2	standard of care
28	Assessing and Comparing the Effect of Diltiazem Gel Versus Nitroglycerin Ointment in Healing Process of Scleroderma Digital Ulcers.	Completed	NCT02801305	Phase 2	Diltiazem Gel 2%;Nitroglycerin Ointment 2%;Vaseline
29	Effect of Bosentan in the Course of Scleroderma Renal Crisis	Completed	NCT01241383	Phase 2	Bosentan
30	Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial	Completed	NCT01538719	Phase 1, Phase 2	Rilonacept
31	A Multi-center Randomized, Double Blind, Placebo-controlled, Pilot Study to Assess the Efficacy and Safety of Riociguat in Scleroderma - Associated Digital Ulcers	Completed	NCT02915835	Phase 2	Riociguat;Placebo
32	Treatment of Refractory Sever Systemic Scleroderma by Injection of Allogeneic Mesenchymal Stem Cells	Completed	NCT02213705	Phase 1, Phase 2
33	A Randomized, Placebo-controlled Phase IIa Clinical Trial to Evaluate the Efficacy and Safety of Subcutaneous Dupilumab in Localized Scleroderma	Recruiting	NCT04200755	Phase 2	Dupilumab 300Mg Solution for Injection
34	A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)	Recruiting	NCT02682511	Phase 2	Oral Ifetroban;Oral Placebo
35	Sildenafil for Early Pulmonary Vascular Disease in Scleroderma	Recruiting	NCT04797286	Phase 2	Sildenafil
36	A Phase 2 Open-Label Pilot Study of the Safety and Tolerability of Ixazomib Administered Orally to Patients With Scleroderma-Related Interstitial Lung Disease	Recruiting	NCT04837131	Phase 2	Ixazomib
37	A Phase II, Randomised, Double Blind, Placebo-controlled Study of the Pharmacokinetics, Pharmacodynamic Effects, and Safety, of Oral FT011 in Participants With Diffuse Systemic Sclerosis	Active, not recruiting	NCT04647890	Phase 2	FT011;Placebo
38	Scleroderma Lung Study III (SLS III): Combining the Anti-fibrotic Effects of Pirfenidone (PFD) With Mycophenolate (MMF) for Treating Scleroderma-related Interstitial Lung Disease	Active, not recruiting	NCT03221257	Phase 2	Pirfenidone (PFD);Placebo (Plac);Mycophenolate Mofetil (MMF)
39	A Phase 1/2 Study of a Combination of FCX-013 (Genetically-Modified Autologous Human Dermal Fibroblasts) Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea)	Terminated	NCT03740724	Phase 1, Phase 2	veledimex
40	Placebo Controlled Trial of Bosentan vs Placebo in NYHA Class I/II Scleroderma Patients With Exercise Induced Pulmonary Hypertension	Terminated	NCT00377455	Phase 2	Bosentan;Placebo
41	A Phase 2, Proof-Of-Concept, Multicenter, Randomized, Double-Blind, Placebo- Controlled, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Pomalidomide (CC-4047) in Subjects With Systemic Sclerosis With Interstitial Lung Disease	Terminated	NCT01559129	Phase 2	Pomalidomide (CC-4047);Placebo
42	A Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma	Terminated	NCT01545427	Phase 2	Imatinib mesylate
43	A Pilot Study to Assess the Safety and Efficacy of Sarilumab in Halting Progression of Morphea	Withdrawn	NCT03679845	Phase 1, Phase 2	Sarilumab
44	Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma	Completed	NCT02426229	Phase 1	dabigatran etexilate
45	A Phase 1, Randomized, Double-blind, Placebo-controlled Study of the Safety and Tolerability of MEDI-551 in Scleroderma	Completed	NCT00946699	Phase 1
46	A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma	Completed	NCT00930683	Phase 1	MEDI-546
47	Comparative Effectiveness Trial of Topical Calcipotriene, Clobetasol, and Tacrolimus in the Treatment of Pediatric Plaque Morphea	Withdrawn	NCT02680717	Phase 1	Clobetasol;Calcipotriene;Tacrolimus
48	Fractional Carbon Dioxide Laser Versus UVA1 Phototherapy for Treatment of Localized Scleroderma: A Clinical & Immunohistochemical Comparative Study	Unknown status	NCT02002897
49	Adult-onset Generalized Morphea : A Retrospective Multicenter Study	Unknown status	NCT04264728
50	Pilot Study of descriPtion of cicatriSation Rates of Digital Ulcers in Systemic scleroDerma	Unknown status	NCT04319120

Search NIH Clinical Center for Localized Scleroderma

Sources

Genetic Tests for Localized Scleroderma

Sources

Anatomical Context for Localized Scleroderma

Organs/tissues related to Localized Scleroderma:

MalaCards : Skin, Lung, Skeletal Muscle, T Cells, Kidney, Eye, Endothelial

Sources

Publications for Localized Scleroderma

Articles related to Localized Scleroderma:

(show top 50) (show all 2383)

#	Title	Authors	PMID	Year
1	Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. ⁵³ ⁶²	Tomimura S...Sato S	18565735	2008
2	Differential expression of decorin in localized scleroderma following ultraviolet-A1 irradiation. ⁵³ ⁶²	Gambichler T...Kreuter A	17184878	2007
3	Collagen degradation products and proinflammatory cytokines in systemic and localized scleroderma. ⁵³ ⁶²	Becvar R...Stork J	17448296	2007
4	Suggested mechanisms of action of UVA phototherapy in morphea: a molecular study. ⁵³ ⁶²	El-Mofty M...Abouzeid A	15030594	2004
5	Induction of interstitial collagenase (MMP-1) by UVA-1 phototherapy in morphea fibroblasts. ⁵³ ⁶²	Gruss C...Kerscher M	9357412	1997
6	Clinical significance of serum levels of soluble interleukin-2 receptor in patients with localized scleroderma. ⁵³ ⁶²	Ihn H...Takehara K	8736323	1996
7	Increased expression of lysyl oxidase in skin with scleroderma. ⁵³ ⁶²	Chanoki M...Ooshima A	8555021	1995
8	Decreased expression of the human progenitor cell antigen (CD34) in morphea. ⁵³ ⁶²	Skobieranda K...Helm KF	8599452	1995
9	Stimulated expression of decorin and the decorin gene in fibroblasts cultured from patients with localized scleroderma. ⁵³ ⁶²	Izumi T...Nishikawa T	7625849	1995
10	Serum levels of soluble interleukin-2 receptor. A marker of disease activity in localized scleroderma. ⁵³ ⁶²	Uziel Y...Laxer RM	8003062	1994
11	Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. ⁵³ ⁶²	Higley H...Black C	7510487	1994
12	Serum levels of soluble interleukin-2 receptor in systemic and circumscribed scleroderma. ⁵³ ⁶²	Zillikens D...Burg G	1392125	1992
13	Expression of osteonectin, decorin, and transforming growth factor-beta 1 genes in fibroblasts cultured from patients with systemic sclerosis and morphea. ⁵³ ⁶²	Vuorio T...Vuorio E	2023219	1991
14	[The diagnostic importance of research on the lysyl oxidase activity in children with circumscribed scleroderma]. ⁵³ ⁶²	Kudrin VI...Grebeniuk VN	1976287	1990
15	Autoimmune conditions and pancreatic cancer risk in older American adults. ⁶²	Yuan F...Stolzenberg-Solomon RZ	36059225	2023
16	Clinical and therapeutic course in head variants of linear morphea in adults: a retrospective review. ⁶²	Fan W...Gandelman J	36456759	2022
17	Durvalumab-associated generalized morphea with overlapping vitiligo. ⁶²	Martel J...Heberton M	36407485	2022
18	Morphea disease activity during pregnancy: A case series. ⁶²	Walker AM...Jacobe HT	36093764	2022
19	Tocilizumab for refractory morphea in adults: A case series. ⁶²	Lonowski S...Vleugels RA	36353292	2022
20	Linear morphea following Blaschko's line with epidermal downmodulation of friend leukemia integration 1 transcription factor. ⁶²	Hashimoto T...Satoh T	35543915	2022
21	Narrow-band reflectance spectrophotometry and infrared thermography for assessment of skin lesions in localized scleroderma. ⁶²	Szczepanek M...Lis-Swiety A	35925826	2022
22	Skin fibrosis associated with keloid, scleroderma and Jorge Lobo's disease (lacaziosis): An immuno-histochemical study. ⁶²	Tafuri WL...Sotto MN	36183172	2022
23	Fat Grafting for the Treatment of Localized Scleroderma: Confusion in the Current Clinical Practice. ⁶²	Wang HC	36075042	2022
24	Clinical, epidemiological, trichoscopic and histopathological features of linear morphea on the scalp. ⁶²	de Marsillac PF...Melo DF	35694874	2022
25	Sclerosing tenosynovitis in a patient with pan-sclerotic morphea. ⁶²	Caillault L...Lescoat A	35671975	2022
26	The value of dermoscopy and high-frequency ultrasound in staging morphea. ⁶²	Zhang S...Liu J	36420557	2022
27	JAAD Game Changers∗: Inflammatory arthritis in pediatric patients with morphea. ⁶²	Cotton CH	35934212	2022
28	Tocilizumab for Corticosteroid-Refractory Immune Checkpoint Inhibitor-Induced Generalized Morphea. ⁶²	Blaise M...Montaudie H	36449277	2022
29	Rare presentation of calcification associated with long-standing linear morphea. ⁶²	Owen JJ...Bicknell LM	36416615	2022
30	Circumscribed Morphea of the Scalp: An Entity to Be Considered in the Differential Diagnosis of Cicatricial Alopecia. ⁶²	Romagnuolo M...Boggio F	36407637	2022
31	Prevalence and Incidence of Localized Scleroderma: A Qualitative Systematic Review. ⁶²	Mahmood F...Netchiporouk E	36225142	2022
32	Juvenile localized scleroderma: A single-centre experience from India. ⁶²	Jindal AK...Singh S	36413107	2022
33	Clinical and laboratory characterization of patients with localized scleroderma and response to UVA-1 phototherapy: In vivo and in vitro skin models. ⁶²	Tognetti L...Rubegni P	35324032	2022
34	The co-occurrence of segmental vitiligo and linear morphea in a pediatric patient and a review of the literature. ⁶²	Kahle J...Shah SD	36379693	2022
35	A case of anti-RNA polymerase III antibody-positive systemic sclerosis with generalized morphea-like lesions correlated with elevation of peripheral eosinophil counts. ⁶²	Sasaoka Y...Fujimoto M	35751638	2022
36	Gastrointestinal involvement in systemic sclerosis: An updated review. ⁶²	Nassar M...El-Kassas M	36397401	2022
37	Tumor necrosis factor-α inhibitor-induced morphea and psoriasiform dermatitis in a pediatric patient with Crohn's disease. ⁶²	Reinhart JP...Tollefson MM	36385392	2022
38	Linear morphea with overlying lichen sclerosus and calcinosis cutis associated with juvenile dermatomyositis. ⁶²	Kaur M...Alam A	36384242	2022
39	Bullous lichen sclerosus-generalized morphea overlap syndrome improved by tofacitinib. ⁶²	Liu L...Xiao R	36254686	2022
40	Evaluation of risk in chronic cutaneous inflammatory conditions for malignant transformation. ⁶²	Ju T...Nouri K	36251409	2022
41	Efficacy and Safety of Ablative Fractional Laser-Assisted Delivery of Methotrexate in Adults with Localized Scleroderma: A Randomized and Controlled Clinical Trial. ⁶²	Guo Q...Xiong H	36365080	2022
42	Serum Levels of Selected IL-1 Family Cytokines in Patients with Morphea. ⁶²	Szczepanik-Kulak P...Krasowska D	36362603	2022
43	Indurated plaques on the back: distinguishing stiff skin syndrome from scleredema and morphea. ⁶²	Raef HS...Fedeles F	34411278	2022
44	Concentrations of metalloproteinase-1 in patients with morphea treated with phototherapy: a preliminary study. ⁶²	Malewska-Wozniak A...Adamski Z	36457686	2022
45	Fat transplantation induces dermal adipose regeneration and reverses skin fibrosis through dedifferentiation and redifferentiation of adipocytes. ⁶²	Wang J...Lu F	36210466	2022
46	Adipose Tissue Grafting for the Treatment of Morphea En Coup De Sabre: A Simple Filler or an Emerging Cellular Therapy? ⁶²	El Omari M...Ait Benhamou R	36407158	2022
47	Morphea After Liposuction Ultrasonography. ⁶²	Araneda-Ortega P...Wortsman X	35023212	2022
48	Leg ulcers in morphea plaques. ⁶²	Kie?ler B...Dissemond J	36075870	2022
49	Adipose-derived stem cells attenuate skin fibrosis and improve fat retention of localized scleroderma mouse model. ⁶²	Wang HC...Wang X	36206077	2022
50	Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma. ⁶²	Fixsen E...Kheterpal M	36446107	2022

Sources

Genes for Localized Scleroderma

Genes related to Localized Scleroderma (0 elite genes):

(show all 24)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MMP1	Matrix Metallopeptidase 1	Protein Coding	17.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	18565735 15030594 9357412
2	DCN	Decorin	Protein Coding	16.19	DISEASES inferred ¹⁴ Novoseek inferred ⁵³ GeneCards inferred via : Publications (show sections)	7625849 17184878 2023219
3	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	8.58	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1392125 8736323 8003062
4	LOX	Lysyl Oxidase	Protein Coding	6.69	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8555021 1976287
5	TSSK1B	Testis Specific Serine Kinase 1B	Protein Coding	6.21	DISEASES inferred ¹⁴
6	CTSK	Cathepsin K	Protein Coding	5.92	DISEASES inferred ¹⁴
7	TOP1	DNA Topoisomerase I	Protein Coding	5.86	DISEASES inferred ¹⁴
8	H2AC18	H2A Clustered Histone 18	Protein Coding	5.86	DISEASES inferred ¹⁴ ¹⁴
9	SNRNP70	Small Nuclear Ribonucleoprotein U1 Subunit 70	Protein Coding	5.83	DISEASES inferred ¹⁴
10	CD34	CD34 Molecule	Protein Coding	5.71	DISEASES inferred ¹⁴
11	COL1A2	Collagen Type I Alpha 2 Chain	Protein Coding	5.67	DISEASES inferred ¹⁴
12	EXOSC10	Exosome Component 10	Protein Coding	5.66	DISEASES inferred ¹⁴
13	CCN2	Cellular Communication Network Factor 2	Protein Coding	5.66	DISEASES inferred ¹⁴
14	IL4	Interleukin 4	Protein Coding	5.57	DISEASES inferred ¹⁴
15	IL6	Interleukin 6	Protein Coding	5.52	DISEASES inferred ¹⁴
16	FBN1	Fibrillin 1	Protein Coding	5.49	DISEASES inferred ¹⁴
17	CD4	CD4 Molecule	Protein Coding	5.45	DISEASES inferred ¹⁴
18	CD8A	CD8a Molecule	Protein Coding	5.32	DISEASES inferred ¹⁴
19	TNF	Tumor Necrosis Factor	Protein Coding	5.28	DISEASES inferred ¹⁴
20	IL13	Interleukin 13	Protein Coding	5.22	DISEASES inferred ¹⁴
21	FN1	Fibronectin 1	Protein Coding	5.21	DISEASES inferred ¹⁴
22	COL1A1	Collagen Type I Alpha 1 Chain	Protein Coding	5.1	DISEASES inferred ¹⁴
23	F13A1	Coagulation Factor XIII A Chain	Protein Coding	5.07	Novoseek inferred ⁵³	8599452 7510487
24	IL17A	Interleukin 17A	Protein Coding	5.05	DISEASES inferred ¹⁴

Sources

Variations for Localized Scleroderma

Sources

Expression for Localized Scleroderma

Search GEO for disease gene expression data for Localized Scleroderma.

Sources

Pathways for Localized Scleroderma

Pathways related to Localized Scleroderma according to GeneCards Suite gene sharing:

(show all 42)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.94	CD34 CD4 CD8A COL1A2 CTSK IL13
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.79	CCN2 CD4 COL1A2 FBN1 IL13 IL2RA
3	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.38	TNF IL6 IL4 IL2RA IL13 CD4
4	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.27	TNF IL6 IL4 IL2RA IL13 CD4
5	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.27	CD4 COL1A2 IL13 IL2RA IL4 IL6
6	Extracellular matrix organization ⁶⁶ Show member pathways Degradation of the extracellular matrix ⁶⁶	12.7	MMP1 LOX FBN1 DCN CTSK COL1A2
7	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.62	CCN2 IL13 IL2RA IL4 IL6 TNF
8	NF-kappaB Signaling ³	12.55	TNF IL4 IL2RA CD8A CD34
9	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.13	TNF IL4 CD8A CD4
10	Neuroinflammation and glutamatergic signaling ⁷⁴	12.09	TNF IL6 IL4 IL13
11	IL12-mediated signaling events ⁶¹ Show member pathways Immune response IL-12-induced IFN-gamma production ²²	11.95	IL4 IL2RA CD8A CD4
12	Allograft rejection ⁷⁴	11.85	TNF IL4 IL2RA IL13
13	Interleukin-4 and Interleukin-13 signaling ⁶⁶	11.83	TNF MMP1 IL6 IL4 IL13 COL1A2
14	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.82	IL6 IL4 CD4
15	C-MYB transcription factor network ⁶¹	11.76	COL1A2 CD4 CD34
16	Glucocorticoid receptor regulatory network ⁶¹	11.75	MMP1 IL6 IL4 IL13
17	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.74	IL6 CD8A CD4
18	Extrafollicular B cell activation by SARS-CoV-2 ⁷⁴	11.7	TNF IL6 IL4
19	AP-1 transcription factor network ⁶¹	11.7	COL1A2 IL4 IL6 MMP1
20	Th17 cell differentiation pathway ⁷⁴	11.69	CD4 IL2RA IL4 IL6
21	Calcineurin-regulated NFAT-dependent transcription in lymphocytes ⁶¹ Show member pathways Calcium signaling in the CD4+ TCR pathway ⁶¹	11.67	TNF IL4 IL2RA
22	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.67	TNF IL6 CD8A CD4 CD34
23	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.64	TNF MMP1 IL6
24	Inflammatory bowel disease signaling ⁷⁴ Show member pathways Ulcerative colitis signaling ⁷⁴	11.6	TNF IL6 IL4 IL13
25	Lung fibrosis ⁷⁴	11.57	TNF IL6 IL4 IL13 CCN2
26	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.56	TNF IL6 IL4 IL2RA CD8A CD4
27	THC Differentiation Pathway ⁶⁴	11.53	TNF IL4 IL2RA CD4
28	Burn wound healing ⁷⁴	11.51	TNF MMP1 IL6 FBN1 DCN COL1A2
29	Th2 Differentiation ⁶⁵	11.46	IL4 IL2RA IL13 CD4
30	Inflammatory response pathway ⁷⁴	11.32	IL4 IL2RA COL1A2
31	Validated transcriptional targets of AP1 family members Fra1 and Fra2 ⁶¹	11.32	MMP1 IL6 DCN COL1A2
32	Antiviral and anti-inflammatory effects of Nrf2 on SARS-CoV-2 pathway ⁷⁴	11.27	TNF MMP1 IL6
33	Development and heterogeneity of the ILC family ⁷⁴	11.26	IL13 IL4 IL6 TNF
34	amb2 Integrin signaling ⁶¹	11.25	TNF IL6 CCN2
35	IL12 signaling mediated by STAT4 ⁶¹	11.21	IL2RA IL13 CD4
36	Immune infiltration in pancreatic cancer ⁷⁴	11.17	TNF IL6 IL4 IL13
37	Cytokines and inflammatory response ⁷⁴	11.12	CD4 IL13 IL4 IL6 TNF
38	Innate Lymphoid Cells Differentiation ⁶⁵	11.07	TNF IL4 IL2RA IL13 CD8A CD4
39	G-protein signaling_Rap2B regulation pathway ²²	10.96	TNF IL6 IL4 IL13 FBN1 COL1A2
40	IL-9 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	10.79	IL6 IL4 IL13
41	COVID-19 adverse outcome pathway ⁷⁴	10.68	IL6 IL2RA
42	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.35	TNF IL6

Sources

GO Terms for Localized Scleroderma

Cellular components related to Localized Scleroderma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	extracellular matrix	GO:0031012	9.81	MMP1 LOX FBN1 COL1A2 CCN2
2	external side of plasma membrane	GO:0009897	9.8	TNF IL2RA IL13 CTSK CD8A CD4
3	extracellular region	GO:0005576	9.74	CCN2 CD34 CD8A COL1A2 CTSK DCN

Biological processes related to Localized Scleroderma according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of tyrosine phosphorylation of STAT protein	GO:0042531	9.76	IL13 IL4 IL6 TNF
2	microglial cell activation	GO:0001774	9.73	TNF IL4 IL13
3	positive regulation of mononuclear cell migration	GO:0071677	9.71	TNF IL4
4	negative regulation of complement-dependent cytotoxicity	GO:1903660	9.62	IL4 IL13
5	positive regulation of interleukin-10 production	GO:0032733	9.56	IL6 IL4 IL13 CD34
6	connective tissue development	GO:0061448	9.54	LOX CCN2
7	immune response	GO:0006955	9.47	TNF IL6 IL4 IL2RA IL13 CTSK